Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Multi-Center, Multinational, Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A (350mg q12) Versus Placebo in the Prevention of Depression Relapse up to 1 Year in Patients With Major Depressive Disorder Improved After 12 Weeks of Open Treatment With SR58611A (350mg q12)

NCT00345098 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00345098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00345098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Multi-Center, Multinational, Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A (350mg q12) Versus Placebo in the Prevention of Depression Relapse up to 1 Year in Patients With Major Depressive Disorder Improved After 12 Weeks of Open Treatment With SR58611A (350mg q12)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
February 29, 2008
Enrollment
704 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major depression